Imunon’s (IMNN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report published on Thursday,Benzinga reports. The brokerage currently has a $29.00 price target on the stock.

Other equities research analysts also recently issued reports about the company. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research report on Monday, September 23rd. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Imunon in a report on Wednesday, December 11th.

Imunon Stock Down 2.8 %

Imunon stock opened at $0.83 on Thursday. The company’s 50-day moving average price is $0.87 and its 200-day moving average price is $1.07. The company has a market cap of $12.04 million, a PE ratio of -0.44 and a beta of 2.12. Imunon has a twelve month low of $0.48 and a twelve month high of $3.65.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.